Randomised, double-blind, placebo controlled study to assess efficacy of oral nicotinamide (500mg daily) in the treatment and prevention of actinic keratoses.

Authors
Category Primary study
Registry of TrialsANZCTR
Year 2010
INTERVENTION: Oral nicotinamide 500mg daily for four months CONDITION: Actinic keratoses PRIMARY OUTCOME: Reduction in total actinic keratosis (AK) count at 2 and 4 months from baseline SECONDARY OUTCOME: Nil INCLUSION CRITERIA: Men and women > 18 years old. Symmetrically distributed non‐hyperkeratotic AKs on face / scalp/ upper limbs. Minimum of 4 AKs in one or more treatment areas. Patients have received no other treatments for AKs within the last month.
Epistemonikos ID: ea4fccae0fd98c53e1e6e6efc2504c01b73d8ecb
First added on: Aug 25, 2024